A Phase I, Multicenter, Open-label, Randomized Study Assessing the Pharmacokinetics, Safety, and Tolerability of Monthly Doses of Pasireotide i.m. LAR Injection in Patients With Acromegaly and Patients With Carcinoid Disease
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determination of the pharmacokinetic profile of single and monthly doses of pasireotide LAR i.m. injection
in patients with acromegaly and in patients with carcinoid disease
Baseline, D7, D35, D63
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
United States: Food and Drug Administration
CSOM230C2110
NCT00446082
June 2006
January 2013
Name | Location |
---|---|
Stanford University Medical Center Stanford Cancer Center (3) | Stanford, California 94304 |
Cedars Sinai Medical Center SC-3 | Los Angeles, California 90048 |
H. Lee Moffitt Cancer Center/University of South Florida Dept.of H.LeeMoffittCC&RI(1) | Tampa, Florida 33612 |
MD Anderson Cancer Center/University of Texas Gastrointestinal Med. Oncology | Houston, Texas 77030-4009 |